EP4301767A4 - Composés bioréactifs et leurs procédés d'utilisation - Google Patents

Composés bioréactifs et leurs procédés d'utilisation

Info

Publication number
EP4301767A4
EP4301767A4 EP22763916.8A EP22763916A EP4301767A4 EP 4301767 A4 EP4301767 A4 EP 4301767A4 EP 22763916 A EP22763916 A EP 22763916A EP 4301767 A4 EP4301767 A4 EP 4301767A4
Authority
EP
European Patent Office
Prior art keywords
bioreactive
compounds
methods
bioreactive compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22763916.8A
Other languages
German (de)
English (en)
Other versions
EP4301767A1 (fr
Inventor
Lei Wang
Jun Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley, University of California San Diego UCSD filed Critical University of California
Publication of EP4301767A1 publication Critical patent/EP4301767A1/fr
Publication of EP4301767A4 publication Critical patent/EP4301767A4/fr
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C305/00Esters of sulfuric acids
    • C07C305/26Halogenosulfates, i.e. monoesters of halogenosulfuric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63Esters of sulfonic acids
    • C07C309/72Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/77Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing carboxyl groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/78Halides of sulfonic acids
    • C07C309/86Halides of sulfonic acids having halosulfonyl groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/89Halides of sulfonic acids having halosulfonyl groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing carboxyl groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47Y being a hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93Ligases (6)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y601/00Ligases forming carbon-oxygen bonds (6.1)
    • C12Y601/01Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
    • C12Y601/01026Pyrrolysine-tRNAPyl ligase (6.1.1.26)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP22763916.8A 2021-03-01 2022-03-01 Composés bioréactifs et leurs procédés d'utilisation Pending EP4301767A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163155222P 2021-03-01 2021-03-01
US202163214432P 2021-06-24 2021-06-24
PCT/US2022/018381 WO2022187273A1 (fr) 2021-03-01 2022-03-01 Composés bioréactifs et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP4301767A1 EP4301767A1 (fr) 2024-01-10
EP4301767A4 true EP4301767A4 (fr) 2025-05-28

Family

ID=83154435

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22763916.8A Pending EP4301767A4 (fr) 2021-03-01 2022-03-01 Composés bioréactifs et leurs procédés d'utilisation

Country Status (6)

Country Link
US (1) US20250283138A1 (fr)
EP (1) EP4301767A4 (fr)
JP (1) JP2024512297A (fr)
AU (1) AU2022231099A1 (fr)
CA (1) CA3212360A1 (fr)
WO (1) WO2022187273A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022232377A2 (fr) * 2021-04-28 2022-11-03 The Regents Of The University Of California Protéines bioréactives contenant des acides aminés non naturels
EP4452333A1 (fr) * 2021-12-22 2024-10-30 Enlaza Therapeutics, Inc. Anticorps de réticulation
CN117003660B (zh) * 2023-08-09 2026-03-27 四川大学 基于三氟甲基光脱氟-酰氟交换交联的非天然氨基酸及其用途
CN121087130A (zh) * 2025-11-12 2025-12-09 康码芯(上海)智能科技有限公司 一种用于插入非天然氨基酸的方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020072674A1 (fr) * 2018-10-02 2020-04-09 The Regents Of The University Of California Agents de réticulation à cibles multiples et leurs utilisations
CN111302980A (zh) * 2019-12-31 2020-06-19 上海交通大学医学院附属仁济医院 含硫酰氟基团的氨基酸类似物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5590649B2 (ja) * 2007-09-20 2014-09-17 独立行政法人理化学研究所 変異体ピロリジル−tRNA合成酵素及びこれを用いる非天然アミノ酸組み込みタンパク質の製造方法
JP6738326B2 (ja) * 2014-06-06 2020-08-12 ザ スクリプス リサーチ インスティテュート フッ化硫黄(vi)化合物およびそれの製造方法
EP3845661A4 (fr) * 2018-08-31 2022-06-22 Riken Pyrrolysyl-arnt synthétase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020072674A1 (fr) * 2018-10-02 2020-04-09 The Regents Of The University Of California Agents de réticulation à cibles multiples et leurs utilisations
CN111302980A (zh) * 2019-12-31 2020-06-19 上海交通大学医学院附属仁济医院 含硫酰氟基团的氨基酸类似物及其制备方法和应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GAMBINI LUCA ET AL: "Covalent Inhibitors of Protein-Protein Interactions Targeting Lysine, Tyrosine, or Histidine Residues", JOURNAL OF MEDICINAL CHEMISTRY, vol. 62, no. 11, 13 June 2019 (2019-06-13), US, pages 5616 - 5627, XP055898707, ISSN: 0022-2623, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b00561> DOI: 10.1021/acs.jmedchem.9b00561 *
See also references of WO2022187273A1 *
WANG NANXI ET AL: "Genetically Encoding Fluorosulfate-l-tyrosine To React with Lysine, Histidine, and Tyrosine via SuFEx in Proteins in Vivo", LANGMUIR, vol. 140, no. 15, 30 March 2018 (2018-03-30), pages 4995 - 4999, XP055816028, Retrieved from the Internet <URL:https://pubs.acs.org/doi/abs/10.1021/jacs.8b01087> DOI: 10.1021/jacs.8b01087 *

Also Published As

Publication number Publication date
CA3212360A1 (fr) 2022-09-09
AU2022231099A1 (en) 2023-08-31
US20250283138A1 (en) 2025-09-11
EP4301767A1 (fr) 2024-01-10
JP2024512297A (ja) 2024-03-19
WO2022187273A1 (fr) 2022-09-09

Similar Documents

Publication Publication Date Title
EP4329757A4 (fr) Composés hétérocycliques et procédés d&#39;utilisation
EP4301767A4 (fr) Composés bioréactifs et leurs procédés d&#39;utilisation
EP4291201A4 (fr) Composés, compositions et leurs méthodes d&#39;utilisation
EP4037695A4 (fr) Compositions oligonucléotidiques et leurs procédés d&#39;utilisation
EP3958872A4 (fr) Compositions d&#39;oligonucléotides et leurs procédés d&#39;utilisation
EP3968999A4 (fr) Inhibiteurs de fgfr et leurs procédés d&#39;utilisation
EP3790596A4 (fr) Compositions d&#39;oligonucléotides et leurs procédés d&#39;utilisation
EP3775203A4 (fr) Compositions d&#39;oligonucléotides et leurs procédés d&#39;utilisation
MA55890A (fr) Modulateurs de thr-beta et leurs procédés d&#39;utilisation
MA56032A (fr) Composés, compositions et procédés d&#39;utilisation
MA54538A (fr) Inhibiteurs d&#39;apol1 et leurs procédés d&#39;utilisation
EP3941459A4 (fr) Composés de quinoléine et de quinazoline et leurs procédés d&#39;utilisation
MA55381A (fr) Pyridazinones et leurs procédés d&#39;utilisation
EP3893917A4 (fr) Compositions d&#39;il-15 et leurs procédés d&#39;utilisation
EP2152256A4 (fr) Composés activant la télomérase et leurs procédés d&#39;utilisation
EP4211233A4 (fr) Compositions et leurs procédés d&#39;utilisation
EP3886854A4 (fr) Composés pyrrole et pyrazole et leurs procédés d&#39;utilisation
MA56457A (fr) Modulateurs de hsd17b13 et leurs procédés d&#39;utilisation
MA71645A (fr) Pyridazinones et leurs procédés d&#39;utilisation
EP4319813A4 (fr) Multimères de peptide-mhc-immunoglobuline et leurs procédés d&#39;utilisation
EP4329521A4 (fr) Compositions de collagène et leurs procédés d&#39;utilisation
MA55532A (fr) Composés de neuréguline-4 et procédés d&#39;utilisation
EP3965776A4 (fr) Compositions oligosaccharidiques et leurs procédés d&#39;utilisation
EP4048402A4 (fr) Lymphocytes t cytoxiques modifiés et leurs procédés d&#39;utilisation
EP4346815A4 (fr) Composés hétérocycliques et procédés d&#39;utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230921

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40106152

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07K0001107000

Ipc: A61K0047640000

A4 Supplementary search report drawn up and despatched

Effective date: 20250428

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101ALI20250422BHEP

Ipc: G01N 30/72 20060101ALI20250422BHEP

Ipc: C12P 21/02 20060101ALI20250422BHEP

Ipc: C07K 1/107 20060101ALI20250422BHEP

Ipc: A61K 47/68 20170101ALI20250422BHEP

Ipc: A61K 47/64 20170101AFI20250422BHEP